IP Library › Assignment 053181/0133
Patent Assignment
Reel/Frame 053181/0133

Change of Name

Recorded: 2020-07-10 Pages: 6
Assignor
BOSTON BIOMEDICAL, INC.
Executed: 2020-07-01
Assignee
SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
640 MEMORIAL DRIVE, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties (44)
Methods to Target Transcriptional Control at Super-Enhancer Regions
Predicting Response to Alvocidib by Mitochondrial Profiling
Combination Therapies for Treatment of Cancer
Profiling Peptides and Methods for Sensitivity Profiling
Compositions and Methods for Treating Cancers That Are Insensitive to Bcl-2 Inhibitors Using Mcl-1 Inhibitors
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Methods for Monitoring Tumor Lysis Syndrome
Predicting Response to Alvocidib by Mitochondrial Profiling
Patent: 9,901,574 →
Application: 15/134,051 →
Publication: US 2016/0303101
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 15/524,953 →
Publication: US 2018/0280407
Combination Therapies for Treatment of Cancer
Application: 15/750,151 →
Publication: US 2018/0256580
Profiling Peptides and Methods for Sensitivity Profiling
Application: 15/847,697 →
Publication: US 2018/0172673
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/023,360 →
Publication: US 2018/0299432
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/132,270 →
Publication: US 2019/0030017
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/279,623 →
Publication: US 2019/0178873
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 16/382,726 →
Publication: US 2019/0314357
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/425,826 →
Publication: US 2019/0282557
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/545,916 →
Publication: US 2020/0200737
Treatment Regimen for Cancers That Are Insensitive to Bcl-2 Inhibitors Using the Mcl-1 Inhibitor Alvocidib
Application: 16/646,853 →
Publication: US 2020/0276215
Combination Therapies for Treatment of Cancer
Application: 16/665,277 →
Publication: US 2020/0054642
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 16/708,366 →
Publication: US 2020/0276174
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 16/730,810 →
Publication: US 2020/0316084
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/814,398 →
Publication: US 2021/0052568
Combination Therapies for Treatment of Cancer
Application: 16/821,762 →
Publication: US 2020/0215071
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/077,042 →
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/150,110 →
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 62/150,138 →
Combination Therapies for Treatment of Cancer
Application: 62/200,499 →
Profiling Peptides and Methods for Sensitivity Profiling
Application: 62/436,221 →
Compositions and Methods for Treating Bcl-2 Inhibitor Insensitive Subjects Using Mcl-1 Inhibitors
Application: 62/557,635 →
Profiling Peptides and Methods for Sensitivity Profiling
Application: 62/562,990 →
Cyclin-Dependent Kinase Inhibitors in Combination with Tetracyclic Anthracyclines for Treatment of Cancer
Application: 62/657,545 →
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 62/688,228 →
Methods for Monitoring Tumor Lysis Syndrome
Application: 62/745,269 →
Treatment of Acute Myeloid Leukemia (Aml) with Venetoclax Failure
Application: 62/821,342 →
Treatment of Previously Treated Cancers
Application: 62/871,540 →
Treatment of Previously Venetoclax-Treated Cancers
Application: 62/871,665 →
Methods for Monitoring Tumor Lysis Syndrome
Application: 62/871,799 →
Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
Application: 62/871,934 →
Combination Therapies for Treatment of Myelodysplastic Syndrome
Application: 62/944,339 →
Treatment of Previously Treated Cancers
Application: 63/029,938 →
Treatment of Previously Venetoclax-Treated Cancers
Application: 63/029,950 →
Combination Therapies for Treatment of Myelodysplastic Syndrome
Application: 63/037,553 →
Treatment of Cancer
Application: 63/037,561 →
Treatment of Cancer
Application: 63/037,567 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Dec 17, 2014
From: WARNER, STEVEN L; BEARSS, DAVID J
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 034528/0591 →
Assignment of Assignor's Interest Aug 31, 2016
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 039601/0719 →
Assignment of Assignor's Interest Oct 11, 2016
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 040315/0951 →
Assignment of Assignor's Interest Nov 15, 2016
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 040327/0144 →
Security Interest Nov 17, 2016
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 040362/0884 →
Assignment of Assignor's Interest May 5, 2017
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 042418/0427 →
Assignment of Assignor's Interest Mar 15, 2018
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045238/0259 →
Assignment of Assignor's Interest Apr 24, 2018
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045626/0176 →
Assignment of Assignor's Interest Jan 17, 2019
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 048379/0095 →
Assignment of Assignor's Interest Feb 15, 2019
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 048356/0008 →
Assignment of Assignor's Interest May 15, 2019
From: BEARSS, DAVID J.; WARNER, STEVEN L.; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049181/0658 →
Assignment of Assignor's Interest May 15, 2019
From: BEARSS, DAVID J.; WARNER, STEVEN L.; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049181/0766 →
Assignment of Assignor's Interest Aug 7, 2019
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049995/0266 →
Assignment of Assignor's Interest Nov 26, 2019
From: SMITH, SUSAN CAROL; ANTHONY, STEPHEN PATRICK
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051114/0826 →
Assignment of Assignor's Interest Dec 11, 2019
From: BEARSS, DAVID J.; WARNER, STEVEN L.; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051245/0291 →
Assignment of Assignor's Interest Dec 12, 2019
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051263/0135 →
Assignment of Assignor's Interest Jan 6, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051485/0381 →
Assignment of Assignor's Interest Feb 19, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051855/0587 →
Assignment of Assignor's Interest Feb 19, 2020
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051969/0535 →
Assignment of Assignor's Interest Feb 21, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051883/0725 →
Assignment of Assignor's Interest Mar 17, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052141/0019 →
Assignment of Assignor's Interest Apr 7, 2020
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052335/0142 →
Assignment of Assignor's Interest Jun 16, 2020
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052954/0490 →
Merger Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053181/0114 →
Change of Name Apr 27, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 059809/0557 →